Oramed Pharmaceuticals
ORMP
52 hedge funds and large institutions have $16.6M invested in Oramed Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 18 reducing their positions, and 8 closing their positions.
550% more call options, than puts
Call options by funds: $26K | Put options by funds: $4K
0.01% more ownership
Funds ownership: 19.02% → 19.03% (+0.01%)
7% less funds holding
Funds holding: 56 → 52 (-4)
10% less capital invested
Capital invested by funds: $18.6M → $16.6M (-$1.92M)
17% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 18
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$869K |
| 2 |
RC
RBF Capital
San Francisco,
California
|
+$99.1K |
| 3 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
+$57.6K |
| 4 |
SG Americas Securities
New York
|
+$54.1K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$51K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$179K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$167K |
| 3 |
RG
Rathbones Group
Liverpool,
United Kingdom
|
-$122K |
| 4 |
Two Sigma Investments
New York
|
-$106K |
| 5 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$80.6K |
ORMP Hedge Fund Activity: Q1 2025 in Review
52 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q1 2025, worth a combined $16.6M — down 10% from $18.6M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ORMP and 4 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 15 added.
The largest buyer was BML Capital Management, adding an estimated $869K. The largest seller was UBS Group, cutting an estimated $179K.
- 52 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q1 2025, down from 56 in Q4 2024.
- Funds reported $16.6M of Oramed Pharmaceuticals stock for Q1 2025, down 10% quarter-over-quarter.
- 4 funds opened new Oramed Pharmaceuticals positions in Q1 2025 and 8 closed out, a net change of -4 holders.
- The largest Oramed Pharmaceuticals buyer in Q1 2025 was BML Capital Management, an estimated $869K added.
- The largest Oramed Pharmaceuticals seller in Q1 2025 was UBS Group, an estimated $179K sold.
Based on aggregated 13F filings for Q1 2025.